The role of lasers and intense pulsed light technology in dermatology

Zain Husain1
Tina S Alster1,2

1Department of Dermatology, Georgetown University Hospital, 2Washington Institute of Dermatologic Laser Surgery, Washington, DC, USA

Abstract: The role of light-based technologies in dermatology has expanded dramatically in recent years. Lasers and intense pulsed light have been used to safely and effectively treat a diverse array of cutaneous conditions, including vascular and pigmented lesions, tattoos, scars, and undesired hair, while also providing extensive therapeutic options for cosmetic rejuvenation and other dermatologic conditions. Dermatologic laser procedures are becoming increasingly popular worldwide, and demand for them has fueled new innovations and clinical applications. These systems continue to evolve and provide enhanced therapeutic outcomes with improved safety profiles. This review highlights the important roles and varied clinical applications that lasers and intense pulsed light play in the dermatologic practice.

Keywords: laser, intense pulsed light, treatment, dermatology, technology

Laser and intense pulsed light principles

Laser is an acronym, which represents light amplification by the stimulated emission of radiation. An understanding of the fundamental properties of laser light is essential to appreciate its clinical effects on the skin.1,2 First, laser light is monochromatic, meaning that the emitted light is composed of a single wavelength. This is determined by the medium of the laser system through which the light passes. Second, laser light is coherent – traveling in phase spatially and temporally. Third, laser light is collimated – emitted in a parallel manner with minimal divergence.

Laser light may be absorbed, reflected, transmitted, or scattered when applied to the skin. In order for a clinical effect to occur, light must be absorbed by tissue. Absorption of laser light is determined by chromophores – the target molecules found in the skin, which have specific wavelength absorption profiles. The three primary endogenous cutaneous chromophores are water, melanin, and hemoglobin; whereas tattoo ink represents an exogenous chromophore. Upon absorption of laser energy by the skin, photothermal, photochemical, or photomechanical effects may occur. The cutaneous depth of penetration of laser energy is dependent upon absorption and scattering. In the epidermis, there is minimal light scattering, whereas in the dermis there is significant scatter due to the high concentration of collagen fibers. The amount of scattering of laser energy is inversely proportional to the wavelength of light. The depth of laser energy increases with wavelength until the mid-infrared region of the electromagnetic spectrum, at which point dermal penetration becomes more superficial due to increased absorption within tissue water.

The theory of selective photothermolysis proposed by Anderson and Parrish3 in 1983 has been pivotal in the advancement of laser surgery. It explains the mechanism
Treatment of vascular lesions

Vascular lesions are frequently treated with lasers and IPL due to the systems’ ability to specifically target intravascular oxyhemoglobin. This endogenous chromophore has three primary absorption peaks within the visible light spectrum: 418, 542, and 577 nm. Oxyhemoglobin absorbs the laser light, which is subsequently converted to heat and transferred to the vessel wall causing coagulation and vessel closure. Treatment with vascular-specific lasers causes inhomogeneous heating within dermal blood vessels due to their varying sizes, but results in effective and efficient treatment of small- and large-diameter blood vessels.14,18–20 Historically, multiple laser systems were shown to be effective in the treatment of vascular lesions, but several fell out of favor due to high rates of adverse effects. The most commonly used vascular lasers in current clinical practice are the potassium titanyl phosphate (KTP, 532 nm), pulsed dye laser (PDL, 585–595 nm), alexandrite (755 nm), diode (800–810, 940 nm), and neodymium-doped yttrium aluminum garnet (Nd:YAG, 532 and 1,064 nm). In addition, IPL with appropriate filters can be used to treat certain vascular lesions.25

The KTP laser is effective in the treatment of numerous superficial vascular lesions, particularly facial telangiectasias.6,7 Treatments are well tolerated and adverse effects include erythema, edema, and crusting. One of the advantages of the KTP laser is that postoperative purpura and erythema are minimized. Its shorter wavelength results in decreased tissue penetration and limited absorption by hemoglobin in deeper vessels. Given that there is considerable absorption of 532 nm energy by melanin, caution must be exercised when treating patients with darker skin.

The PDL is a highly effective laser for the treatment of a wide range of vascular lesions and is considered the workhorse vascular laser in many practices due to its favorable clinical efficacy and low risk profile. The PDL has successfully been used to treat port-wine stains,8–17 facial telangiectasias,18–20 hemangiomas,21–25 pyogenic granulomas,26 Kaposi’s sarcoma,27 and poikiloderma of Civatte.28 In addition, PDL is highly effective in the treatment of hypertrophic and keloid scars.29–31 Striae distensae,32,33 verrucae,34,35 angiofibromas,36 lymphangiomas, and many other dermatologic conditions.37–49 Fluences ranging 5–10 J/cm² using 3–10 mm spot sizes with a minimal to no pulse overlap reduces unwanted thermal injury. Adverse effects include postoperative purpura, transient dyspigmentation, and rarely vesiculation, crusting, and scarring. Newer PDLs with longer wavelengths and extended pulse durations have enabled deeper tissue penetration and improved clinical outcomes (Figure 1A and B).

IPL has also been used to effectively treat a variety of vascular lesions, including facial telangiectasias, capillary malformations, poikiloderma of Civatte, venous malformations, and infantile hemangiomas.5,50–52 Its noncoherent light emits wavelengths ranging from 420 to 1,400 nm. Filters are used to limit the wavelengths emitted by the device in order to improve dermal penetration and minimize absorption of energy by other chromophores. IPL energy is delivered as a series of single, double, or triple pulse sequences with pulse durations of 2–25 milliseconds and interpulse delays of 10–500 milliseconds. Longer pulse durations are used to more effectively heat deeper vessels, thereby reducing the risk of purpura and hyperpigmentation.

Prominent leg veins are a common cosmetic concern and can be challenging to treat. Sclerotherapy is highly
Lasers and intense pulsed light effective for leg veins and is considered the gold standard treatment; however, it can be associated with significant adverse effects such as ulceration, allergic reactions, and telangiectatic matting. The KTP and PDL lasers as well as IPL have shown efficacy in the treatment of small vessels measuring <1 mm. The treatment of larger and/or deeper vessels requires longer wavelengths and pulse durations. The LP alexandrite (755 nm), diode (800 nm), and Nd:YAG (1,064 nm) lasers have each been successful in eradicating small- to medium-sized veins.55-59

**Treatment of hypertrophic scars, keloids, and striae**

Hypertrophic scars and keloids are abnormal wound responses to cutaneous injury and are marked by excessive collagen formation. They are difficult to treat and have high recurrence rates following conventional treatments such as surgical excision, dermabrasion, radiation, and intralosomal therapy.60-62 Many studies have been published in which scars treated with PDL resulted in improvement in erythema, texture, pliability, and pain, with minimal side effects.29-31,63 Significant clinical improvement of hypertrophic scars is often observed after one or two PDL treatments, with greatest responses observed with the use of lower energy densities (Figure 2A and B). Adjunctive therapies to PDL such as intralosomal corticosteroids or 5-fluorouracil are most useful for resistant keloids and/or actively proliferating hypertrophic scars.65,66 Adverse effects after PDL treatment are mild and include purpura that typically dissipates in several days and temporary dyspigmentation that resolves spontaneously over time. More recently, ablative fractional lasers have been shown to improve hypertrophic scars and are often combined with topical delivery of corticosteroids for improved efficacy.67,68

Striae distensae are common atrophic lesions that are often associated with obesity, pregnancy, puberty, and exogenous steroid use. They initially present as slightly erythematous to pink atrophic bands, termed striae rubra. They gradually become hypopigmented and fibrotic and are referred to as striae alba. Striae have been treated successfully with low-fluence PDL, with stria rubra showing greater clinical response to treatment than mature striae alba.32,63 Fractional ablative and nonablative lasers have also been shown to improve the pigmentation and texture of striae distensae.69,70

**Treatment of pigmented lesions**

Cutaneous pigmented lesions are frequent targets of laser and IPL treatment. QS lasers are highly effective in lightening or eliminating benign epidermal and dermal pigmented lesions such as solar lentigines, ephelides, café au lait macules, seborrheic keratoses, melanocytic nevi, blue nevi, nevi of Ota/Ito, infraorbital hyperpigmentation, drug-induced hyperpigmentation, Becker’s nevi, and nevi spilus. These same lasers have also been used to treat amateur, professional, and traumatic tattoos. The red and infrared wavelengths of the QS lasers target melanin within melanosomes (as is the case with pigmented lesions) and various carbon-based material or organometallic dyes (as is the case with tattoos), with limited injury to adjacent normal tissue.71 A variety of different lasers (including CW and quasi-CW systems) have been used to treat pigmented lesions in the past; however, they are not currently in wide use due to significant risk of scarring and dyspigmentation.72-74 The short pulsed QS and picosecond systems commonly used to treat pigmented lesions and tattoos today include...
Nd:YAG (532 and 1,064 nm), ruby (694 nm), and alexandrite (755 nm) lasers.

The QS ruby was the first system developed to treat pigmented lesions and tattoos and was widely and successfully used; however, its 694 nm wavelength required caution in patients with darker skin tones due to its energy being so strongly absorbed by melanin with a greater risk of hypopigmentation. The subsequent development of QS alexandrite and Nd:YAG lasers were also shown to effectively treat pigmented lesions and tattoos with the advantage that their longer wavelengths could safely treat darker skin and penetrate into the deeper dermis. Most recently, Q-switched lasers that generate picosecond domain pulses have been commercially introduced with an even greater ability to target and destroy cutaneous pigment and ink (Figure 3A and B).

Effective tattoo removal necessitates the use of an appropriate wavelength that is preferentially absorbed by the specific ink color within the tattoo. Black pigment absorbs wavelengths from red through the infrared spectrum.
and can thus be treated with QS ruby, QS alexandrite, or QS Nd:YAG lasers. The QS ruby or alexandrite lasers can safely target blue and green inks since these pigments absorb in the 600–800 nm range, whereas only the 532 nm QS Nd:YAG laser can clear red, orange, and yellow inks. Cosmetic tattoo inks that are typically tan, white, or rust colored are difficult to treat because they frequently contain iron oxide and titanium dioxide compounds that undergo a chemical reaction upon laser irradiation to a black and insoluble form (ferric oxide to ferrous oxide). Professional tattoos are more difficult and require additional sessions to eliminate than amateur tattoos, given the dense dermal concentration of ink in the former. Adverse effects of laser tattoo removal include transient pigmentary alteration (hypo- and hyperpigmentation), systemic allergic or localized granulomatous tissue reactions, ignition of explosive particles in traumatic tattoos, and atrophic scars.

IPL devices have also been used to treat benign pigmented lesions including ephelides and solar lentigines, with significant lesionol improvement observed after a series of monthly treatments. They are relatively ineffective in the treatment of tattoos because of their inability to deliver short pulses that can target and pulverize ink particles.

**Hair removal**

Safe and long-lasting hair reduction in cosmetically undesirable locations can be achieved with a variety of lasers and IPL devices. These systems emit red and infrared light with wavelengths ranging 600–1,200 nm, which are capable of targeting melanin in the hair shaft, follicular epithelium, and hair matrix. Since melanin is also normally present in the epidermis, it presents as another competing source for laser energy absorption and can lead to undesirable epidermal damage. Concomitant epidermal cooling sources help to minimize unwanted thermal injury (particularly in patients with darker skin) during treatment. While pulse durations of 10–100 milliseconds are typically used (in keeping with the thermal relaxation time of most hair follicles), the biological target in laser hair removal is the follicular stem cell, which is located in the bulge region or dermal papilla of the hair follicle. Since these stem cells do not always contain significant amounts of melanin and may not be directly adjacent to the targeted pigmented structures, longer pulse durations than those outlined are often necessary for heat diffusion from the follicular shaft to the desired end-target. Permanent hair reduction without significant adverse effects has been achieved despite the use of prolonged pulse durations.

**Ablative laser resurfacing**

Laser skin resurfacing has evolved significantly over the past 2 decades. It was first popularized in the mid-1990s following the introduction of the pulsed carbon dioxide (CO₂) laser system for the treatment of facial rhytides and atrophic acne scars. The 10,600 nm wavelength emitted by a CO₂ laser is absorbed by intracellular water, resulting in tissue heating and vaporization. The pulsed CO₂ laser produces discrete areas of tissue vaporization while minimizing thermal injury to surrounding tissue that can be associated with scarring and hypopigmentation. Subsequent to the development of the pulsed and scanned CO₂ laser systems, the erbium-doped yttrium aluminum garnet (Er:YAG) laser was introduced. Its 2,940 nm wavelength also resulted in controlled skin ablation with minimal thermal injury. Because the Er:YAG system creates little thermal reaction in the skin, tissue tightening is not as dramatic as that seen after CO₂ laser treatment. On the other hand, the minimal thermal injury created by Er:YAG laser irradiation leads to quicker postoperative healing and fewer side effects.

While numerous cosmetic applications of pulsed and scanned CO₂ and Er:YAG ablative lasers have been reported, they have been most frequently used for facial rejuvenation of photodamaged skin, including rhytides and dyschromia.
Atrophic acne and traumatic scars also can be effectively treated with ablative lasers.\textsuperscript{139,140} Impressive skin tightening has been demonstrated with CO\textsubscript{2} laser skin resurfacing due to the thermal effect on dermal collagen.\textsuperscript{141,142} Ablative lasers have been successfully used to treat verrucae vulgaris, seborrheic keratosis, syringoma, xanthelasma, onychodystrophy, actinic keratosis, and Zoon’s balanitis among other dermatologic conditions.\textsuperscript{143–145}

While extremely effective, prolonged side effects and complications associated with ablative laser resurfacing were reported.\textsuperscript{146–150} Frequently encountered posttreatment reactions include intense erythema and edema, which can persist for several weeks to months.\textsuperscript{146} Milia and acne can be experienced, particularly in individuals with a previous history of acne and in treatment of scars.\textsuperscript{147} Infections are relatively uncommon, but patients with a history of herpes labialis should receive prophylactic oral antiviral therapy to reduce the incidence of latent herpes reactivation.\textsuperscript{151,152} Postinflammatory hyperpigmentation occurs not infrequently, particularly in patients with darker skin tones or after aggressive laser treatment.\textsuperscript{153} Delayed hypopigmentation is far less common – typically observed several months (>6 months) after treatment\textsuperscript{147} and develops more frequently with CO\textsubscript{2} laser ablation than with Er:YAG. Hypertrophic scarring is another infrequent complication that can result from aggressive laser technique, infection, and poor wound management. Rarely seen is ectropion formation, which can occur when lax periocular skin is vaporized in patients with a previous history of lower blepharoplasty.

Nonablative laser resurfacing

Nonablative laser systems were developed primarily to reduce the risk of adverse effects and the extensive postoperative recovery period associated with ablative laser resurfacing. There are several nonablative laser and IPL devices, most of which emit infrared light. They include the Nd:YAG (1,064 and 1,320 nm), diode (980 and 1,450 nm), erbium: glass (Er:glass, 1,540 nm), and IPL (500–1,200 nm) systems. Similar to ablative lasers, they primarily target dermal water, which causes collagen heating and dermal remodeling. Unlike their ablative counterparts; however, epidermal injury and tissue vaporization does not occur due to the concomitant application of epidermal cooling. Clinical applications of nonablative lasers include facial and nonfacial rhytides and scars.\textsuperscript{154–157} Treatments are typically performed in a series of three or more monthly sessions to achieve optimal clinical results.\textsuperscript{154–157} Because the epidermis is spared from damage, nonablative lasers can be safely used on nonfacial skin and are associated with speedier recovery and lower incidence of postoperative side effects compared with ablative lasers. Posttreatment erythema and edema resolve within 24–48 hours, which is typical, but other significant side effects are rare. Blister formation is an uncommon complication stemming from insufficient epidermal cooling.

**Fractional laser skin resurfacing**

Fractional photothermolysis was introduced in 2004,\textsuperscript{158} thereby revolutionizing laser skin resurfacing. Fractional laser systems target tissue water and produce microscopic treatment zones of controlled width, depth, and densities in the skin. These three-dimensional thermal damage zones are referred to as “microscopic thermal zones” (MTZs) and are the fundamental units of fractional photothermolysis. In contrast to full-field resurfacing, only a fraction of the skin is removed. The energy in the fractionated columns of the laser induces thermal damage without affecting neighboring tissue. Adjacent unaffected tissue serves as a source for healing and rapid epidermal repair via migration. The targeted damage with MTZ stimulates neocollagenesis and collagen remodeling.\textsuperscript{159,160} As a result, fractionated photothermolysis minimizes the risk of complications and reduces recovery times seen with the aforementioned resurfacing lasers. Fractional technology has been applied to both ablative and nonablative laser systems. Ablative fractional lasers produce MTZ of epidermal and dermal tissue vaporization, whereas nonablative fractional lasers induce epidermal and dermal coagulation without tissue vaporization.

Several nonablative fractional lasers are commercially available, including Nd:YAG (1,440 nm), diode (1,440 nm), erbium (1,410, 1,540, and 1,550 nm), and thulium (1,927 nm) laser systems. These lasers are frequently used for the treatment of facial and nonfacial rhytides, dyschromia, and scars. Although facial skin treatments result in superior clinical outcomes, nonfacial skin treatments are also impressive. Clinical studies have demonstrated significant improvement of facial rhytides, atrophic acne scars, hypertrophic scars, and enlarged pores when treated with various nonablative fractional lasers\textsuperscript{161–168} (Figure 4A and B). The successful treatment of melasma with nonablative lasers has been less consistent.\textsuperscript{169,170}

The ablative CO\textsubscript{2} and Er:YAG fractionated lasers are both highly effective in the treatment of photaged skin and yield similar clinical efficacy and rapid recovery.\textsuperscript{171–173}
Ablative fractionated lasers have also been used to successfully treat acne scars, including severe scars on a variety of anatomic locations\(^{174,175}\) (Figure 5A and B). Treatments are typically performed as a single procedure due to their robust clinical results compared with nonablative fractional lasers.

Although fractionated ablative and nonablative lasers have a superior safety profile compared with their nonfractionated counterparts, side effects and complications can still occur. Patients often encounter posttreatment erythema and edema following nonablative fractional resurfacing that typically resolve within 3 days.\(^{176}\) Erythema that extends beyond 4 days is considered prolonged and is reported in <1% of patients. In contrast, erythema that lasts beyond 1 month following ablative fractional laser treatment is considered prolonged and is seen in ~12.5% of patients.\(^{177}\) A 590 nm light-emitting diode system has been shown to reduce postfractional laser erythema.\(^{178}\) Herpes simplex virus infection is the most common infectious complication following fractionated laser treatment, affecting up to 2% of patients.\(^{177}\) It is generally recommended to treat patients prophylactically if they have a history of facial herpes simplex virus or if perioral laser treatment is performed. Bacterial infection is comparatively low with an incidence of 0.1%.\(^{177}\) Antibacterial prophylaxis can be useful prior to ablative fractionated laser resurfacing. In addition, transient acneiform eruptions can...
develop following fractionated laser resurfacing in up to 10% of patients, especially those with a history of acne. 177 Moderate-to-severe acne flares can be treated with a short course of tetracycline-based antibiotics. Milia also develop in approximately 20% of treated patients and can be minimized by avoiding occlusive emollients. 177 Postinflammatory hyperpigmentation is another possible complication, although less frequently encountered when compared with nonfractional lasers. The incidence can be >12% in patients with darker phototypes (III–VI). 179 Delayed-onset hypopigmentation, hypertrophic scarring, and the development of vertical and horizontal bands are extremely rare complications of ablative fractional resurfacing. 180–182

Laser phototherapy

The effective treatment of a variety of dermatologic diseases with ultraviolet (UV) phototherapy has long been established. Psoriasis has been treated with broadband and narrowband UVB light as well as psoralen with UVA for decades with significant clinical response. The xenon chloride excimer laser (308 nm) has been used to treat psoriasis as well, demonstrating clearing of psoriatic plaques with fewer treatments than narrow-band UVB treatment. 183–186 One of the significant advantages of the excimer laser is that it targets only affected areas of skin, thereby preventing unnecessary exposure of normal tissue to UV radiation. Numerous studies have shown the clinical efficacy of the excimer laser for the treatment of various forms of psoriasis, including a multicenter study which demonstrated that 84% of patients reached 75% improvement or better after 10 or fewer treatments. 184 Treatments are often well tolerated, but adverse effects include blistering, erythema, and hyperpigmentation. Although clinically effective, treatment limitations include relative expense of therapy, time constraints when faced with large surface areas of psoriasis, and unknown risk of carcinogenesis.

The excimer laser has also been found to be as effective as narrow-band UVB in the treatment of vitiligo, with studies demonstrating greater than 75% repigmentation in patches of vitiligo after treatment. 187 These significant response rates are achieved in a relatively short treatment time period compared with traditional phototherapy. 188 Other conditions that have shown clinical response to the excimer laser include atopic dermatitis, alopecia areata, allergic rhinitis, folliculitis, granuloma annulare, lichen planus, mycosis fungoides, palmoplantar pustulosis, pityriasis alba, CD30+ lymphoproliferative disorder, leukoderma, prurigo nodularis, localized scleroderma, and genital lichen sclerosus. 189

Conclusion

Laser and IPL systems have diverse clinical applications throughout the field of dermatology and are constantly evolving. These technologies have facilitated the treatment of benign vascular and pigmented lesions, unwanted hair, tattoos, hypertrophic scars, keloids, rhytides, as well as dermatologic diseases such as psoriasis and vitiligo. Laser resurfacing, including ablative and nonablative fractional treatments have yielded excellent cosmetic results with improved safety profiles and recovery. Refinement of existing devices and the development of novel technologies will continue to expand the role of lasers and IPL in the future and enable practitioners to deliver the most cutting-edge and sophisticated treatments for a wider range of cutaneous conditions.

Disclosure

The authors report no conflicts of interest in this work.

References


Clinical, Cosmetic and Investigational Dermatology

Publish your work in this journal

Clinical, Cosmetic and Investigational Dermatology is an international, peer-reviewed, open access, online journal that focuses on the latest clinical and experimental research in all aspects of skin disease and cosmetic interventions. All areas of dermatology will be covered; contributions will be welcomed from all clinicians and basic science researchers globally. This journal is indexed on CAS. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: http://www.dovepress.com/clinical-cosmetic-and-investigational-dermatology-journal

40

Clinical, Cosmetic and Investigational Dermatology 2016:9


